E. A. Lyamtseva

E. A. Lyamtseva

Auto-generated profile, based on publicly available information

E. A. Lyamtseva

State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Biological Agency

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2020 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
PDF file
AMA. O. Malysheva
A. O. Malysheva
GKGalina Kodina
Galina Kodina
ELE. A. Lyamtseva
E. A. Lyamtseva
NTN. A. Taratonenkova
N. A. Taratonenkova
ALAleksandr S. Lunev
Aleksandr S. Lunev
ЛАЛямцева Е. А
Лямцева Е. А
Most important quality attributes of any radiopharmaceutical (RPh) are its radiochemical purity (RCP) or content of radiochemical impurities (RCIs) that have to comply with respective norms and limits. However, at present, there is no unified approach to validation of analytical methods in the context of highly radioactive samples.The aim of the study was to develop an approach to validation of methods for determination of RCI content in RPhs.Materials and methods: the authors determined the content of RCIs in a radiopharmaceutical formulation containing a complex of technetium-99m and methylenediphosphonic acid by the radiometric method after isolation of impurities from the main compound by thin-layer chromatography using silica gel and methyl ethyl ketone (for sodium pertechnetate determination) and silica gel and 13.6% sodium acetate solution (for determination of hydrolysed reduced technetium-99m). The radioactivity was registered by a chromatogram scanner with a detector of gamma-rays with energies from 0.05 to 1.5 MeV.Results: the paper analyses existing official approaches to validation of analytical procedures and compares them with the results of experimental studies described in available publications. It assesses the validation parameters for compliance with the acceptance criteria set forth in the current regulations and substantiates selectivity of chromatographic determination of impurities under the selected test conditions. Coefficients of variation for repeatability, reproducibility, and accuracy did not exceed 4.5, 2.8, and 8.9%, respectively, given the relative error of not more than 10.5%. The study demonstrated signal linearity for the 10-fold dilution of the standardised sodium pertechnetate solution, it also demonstrated correspondence between the applied and detected radioactivity when performing the test in the impurity content range of 0.5–5%. The validation procedure was associated with significant radiation burden for the personnel of the quality control laboratory.Conclusions: the authors suggested a methodological approach to validation of methods for determination of RCI content in technetium-99m-based RPhs. This approach may be used in the development of a guideline on validation of analytical methods for RCP/RCI determination in RPhs, or for introduction of relevant sections into existing documents.

31 August 2026 in Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
PDF file
AMA. O. Malysheva
A. O. Malysheva
ELE. A. Lyamtseva
E. A. Lyamtseva
ALAnton Larenkov
Anton Larenkov
АМА. О. Малышева
А. О. Малышева
ЕЛЕ. А. Лямцева
Е. А. Лямцева
АЛА. А. Ларенков
А. А. Ларенков
INTRODUCTION. The most important quality indicators of a radiopharmaceutical (RPh) are its radiochemical purity (RCP) or radiochemical impurity content (RCI), the values of which are standardized. Mandatory control testing of lyophilisates to assess composition, authenticity, apyrogenicity, and sterility is guaranteed by the manufacturer. Evaluation of the technetium-99m labeling process for lyophilisates, which can be influenced by numerous factors, is usually the responsibility of the end user. The methods presented in quality regulatory documents were developed in the 1970s and 1980s, and some of them require adjustment due to the upgrading of measurement instrumentation and the emergence of new materials. AIM. To summarize the 10-year experience (2015–2025) of an accredited testing laboratory by analyzing the quality control results of 99m Tc-RPhs routinely used in clinical practice, to adjust existing analytical methods specified in manufacturers’ quality documents, and to develop new ones. MATERIALS AND METHODS. Quality control of technetium-99m radiopharmaceuticals was performed using the most significant parameters, RCP/RCI, following the methods presented in the approved quality documents of the manufacturers. The radiopharmaceuticals were prepared from lyophilisates and eluate (Na 99m TcO 4 solution) from 99 Mo/ 99m Tc generators of the GT-2M, GT-4K, and GT-5K types. RESULTS. During the 10 years of operation, the accredited laboratory tested 1106 radiopharmaceuticals. Analytical methods for determining RCP/RCI based on thinlayer chromatography (TLC) were identified and tested for the radiopharmaceuticals “Macrotech, 99m Tc,” “Bromezida, 99m Tc,” and “Pentatech, 99m Tc,” replacing the previously used filtration and high-voltage agarose gel electrophoresis methods. For the radiopharmaceutical “Technemek, 99m Tc,” a chromatographic method was tested instead of determining the radiochemical composition indicator. This method allows simultaneous determination of the technetium-99m complex with dimercaptosuccinic acid (retardation factor, R f 0.45–0.70), free Na 99m TcO 4 (R f 0.9–1.0) and hydrolyzed reduced technetium-99m (R f 0–0.15). CONCLUSIONS. Of the total number of radiopharmaceuticals tested over the 10-year period, only a limited number of radiopharmaceuticals (3.2%) had an RCP below the acceptable level. The advantages of the proposed methods lie in the simplification of the analytical procedures, which will allow their use in a medical facility immediately before administration of the radiopharmaceutical to the patient, as well as reliable determination of the most important quality indicator of the radiopharmaceutical (RCP), which is responsible for accumulation in the target organ. The developed methods can be proposed for inclusion in draft pharmacopeial monographs and to the manufacturers of lyophilisates for their incorporation into quality regulatory documents.

25 November 2022 in Drug development & registration
Verified
Journal Article
Open access
PDF file
AMA. O. Malysheva
A. O. Malysheva
GKGalina Kodina
Galina Kodina
ELE. A. Lyamtseva
E. A. Lyamtseva
Introduction. Rhenium-188 has found wide application in nuclear medicine for the treatment of metastatic lesions of the skeletal system and joint diseases such as rheumatoid arthritis and synovitis. Also, 188Re-radiopharmaceuticals are being developed for the palliative treatment of hepatocellular carcinoma and others. Immediately after the first clinical trials of 188Re-radiopharmaceuticals, when information on clinically effective administered doses for radionuclide activity was obtained, the use of sodium perrenate, 188Re solutions with high volume activity for radiopharmaceutical synthesis and, consequently, additional concentration of obtained from the generator solutions became extremely relevant.Aim. Development of the technique for concentration of sodium perrenate, 188Re solution, obtained from the 188W/188Re generator "GREN-1" (State Research Center of the Russian Federation IPPE named after Leipunsky, Obninsk, Russia) under laboratory conditions, and comparison of the quality indicators of the resulting product and Na188ReO4 solution obtained from the generator with an automatic concentration module NEPTIS-TH (IRE, Belgium).Materials and method. The objects of this study were eluates from the 188W/188Re generator "GREN-1" manufactured by the IPPE JSC (Obninsk, Russia) and the materials used in the production and quality control of these generators, as well as the generator produced by the National Institute of Radioelements (IRE, Belgium) with an automatic concentration module NEPTIS-TH. The following methods were used to control the quality of sodium perrhenate, 188Re solutions: radiometry, thin layer chromatography, potentiometry, potentiometric titration, atomic absorption spectroscopy.Results and discussion. The efficiency of concentration of the eluate from the "GREN-1" generator using cartridges filled with cation exchanger Dowex® 50WX8 (100–200 mesh) (Sigma-Aldrich, USA, Cat. No. 217506) and Al2O3 with pH 4 (100–200 mesh), and the IRE generator using the automatic NEPTIS-TH module was studied. The yield of rhenium-188 after concentration was 75–85 %. As a result of the concentration process, there is no proportional increase in the content of chemical impurities, and it is possible to obtain cleaner solutions for the content of metals such as Fe, Zn, Cu and others. It was found that in the routine use of generators, the value of the volume radioactivity of the obtained concentrated sodium perrhenate, 188Re solution should not exceed 7.4–8.0 GBq/ml.Conclusion. The conducted studies have shown that the task of concentration of sodium perrenate, 188Re solutions with high volume activity of appropriate quality for the preparation of radiopharmaceuticals for radionuclide therapy can be solved using quite affordable materials, namely a sequence of cartridges. The use of an automatic module is more preferable than the use of manual assembly of a sequence of cartridges, based on the guaranteed quality assurance of the resulting sodium perrenate, 188Re solution and reducing the dose burden on personnel. However, the conducted studies have shown that the tested concentration module is incompatible with the domestic generator, so the system proposed for the study was not registered in Russia. The results obtained in this work will be used to organize the industrial production of domestic modules and cassettes in complete set with "GREN-1" generator.